Skip to content

Curative effect were observed on treating persistent allergic rhinitis by different intensity acupoints: a randomized controlled trial

Curative effect were observed on treating persistent allergic rhinitis by different intensity acupoints: a randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-15007370
Enrollment
Unknown
Registered
2015-11-09
Start date
2015-12-10
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

allergic rhinitis

Interventions

Group 1:Compound white mustard formula ginger apply for 2 hours
Group 2:Compound white mustard formula honey apply for 2 hours
Group 3:Compound white mustard formula honey apply for 8 hours
Sham acupoint application group:Millet honey apply 8 hours

Sponsors

The Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
8 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. meeting the diagnostic criteria of persistent allergic rhinitis disease; 2. the age of patients between 8 and 60 years old, male or female; 3. acquiring informed consent from patients, and they receive treatments and examinations complyingly in the trial.

Exclusion criteria

Exclusion criteria: 1. With other severe diseases of respiratory, circulatory, urinary tract, blood, nervous and endocrine system, and suffer from malignant tumors, psychopath; 2. Having received application of traditional Chinese medicine, and having been receiving medicine or other therapy; 3. Pregnant women or women in lactation; 4. Acupoint application points have a skin lesion or patients are scar constitution; 5. With particularly sensitive to medicines or dressings; 6. Have a history of drug abuse or or have a history of alcohol abuse, and alcoholism cannot stopped during the test; 7. Individual is considered unsuitable for the research by the researche.

Design outcomes

Primary

MeasureTime frame
IgE;IgG;EOS;Sympton score;Signs score;

Contacts

Public ContactSonghe Jiang
jshwz@126.com+86 13600661860

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026